Study Procedure | Screening visit | During SABR Protocol treatment | Follow-up | |||
---|---|---|---|---|---|---|
During SABR treatment | End of SABR treatment | Year 1–2 First month and every 3months | Years 3 Every 6 months | End of study | ||
Medical history and physical examination | X | X | X | X | ||
Informed consent | X | |||||
Concomitant medications | X | X | X | X | X | |
Bood counts, Serum chemistry PSA/Testosterona | X | X | X | X | ||
Urinary or rectal comorbidities | X | X | X | X | X | X |
Adverse events | X | X | X | X | X | X |
Prostate MRI | X | X | X* | |||
Standard imaging work up | X# | |||||
PET–TC (PSMA or Choline in High Risk | X# | |||||
QoL questionaires | X | X | X | X | X | |
Urinary and rectal events and grades | X | X | X | X | X | X |
Survival | X | X | X | X | X |